AGENUS
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. It was established in 1994 and is headquartered in Lexington, Massachusetts.
AGENUS
Industry:
Biotechnology Medical Medical Device Therapeutics
Founded:
1994-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.agenusbio.com
Total Employee:
501+
Status:
Active
Contact:
(781)674-4400
Total Funding:
346.14 M USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA Cloudflare Hosting Cloudflare CDN CloudFront ASP.NET Ajax Google Analytics IP Anonymization Q4Web Hosting
Similar Organizations
Adaptimmune
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
DNAnexus
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Haemonetics
Haemonetics is a provider of blood and plasma supplies and services.
Halozyme Therapeutics
Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Sutro Biopharma
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-12-27 | PhosImmune | PhosImmune acquired by Agenus | 44.9 M USD |
| 2015-04-08 | Celexion | Celexion acquired by Agenus | 4 M USD |
| 2014-01-13 | 4-Antibody AG | 4-Antibody AG acquired by Agenus | N/A |
Investors List
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Post-IPO Debt - Agenus
Incyte
Incyte investment in Post-IPO Equity - Agenus
Iroquois Capital
Iroquois Capital investment in Post-IPO Equity - Agenus
Hudson Capital Group
Hudson Capital Group investment in Post-IPO Equity - Agenus
Downsview Capital
Downsview Capital investment in Post-IPO Equity - Agenus
Key Employee Changes
| Date | New article |
|---|---|
| 2023-07-20 | Agenus Expands Executive Leadership Team |
Official Site Inspections
http://www.agenusbio.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.92 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Agenus"
Agenus - Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines. CPM development is a par…See details»
Team - Agenus
Nils most recently served as Vice President, Global Academic & Strategic Partnerships (GMA ex-China) at BeiGene, where he also previously served as Vice President, Head of Medical …See details»
Agenus - LinkedIn
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations ...See details»
Agenus Inc. - Investor Relations
Nov 7, 2024 [email protected] Quick Links. SEC Filings; Information Request Form; Investor Email Alerts. To opt-in for investor email alerts, please enter your email address in the …See details»
Our History - Agenus
Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to …See details»
Agenus - Crunchbase Company Profile & Funding
Organization. Agenus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number (781)674-4400; Agenus …See details»
Agenus Inc. (AGEN) Company Profile & Facts - Yahoo Finance
See the company profile for Agenus Inc. (AGEN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Agenus Reports Fourth Quarter and Full Year 2023 Results
Mar 14, 2024 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various …See details»
Agenus Inc. - Agenus Expands Executive Leadership Team
Jul 20, 2023 Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan …See details»
Agenus Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Agenus has 5 employees across 5 locations and $156.31 m in annual revenue in FY 2023. See insights on Agenus including office locations, competitors, revenue, financials, …See details»
Patients & Care Partners - Agenus
To learn more about our clinical trials, patient advocacy initiatives or to discuss ways to collaborate, please contact us at: +1 781-384-2053 or [email protected]. Agenus Inc. …See details»
Agenus Announces Updated Phase 1 Data and Progress on …
Apr 12, 2024 Updated Phase 1 data demonstrate a 12-month overall survival (OS) of 71% and 18-month OS of 62% Company plans to discuss encouraging Phase 2 interim results with the …See details»
Agenus Prioritizes Resources to Accelerate Registration and ...
Aug 23, 2023 The plan will reduce operating expenses across Agenus' global organization by concentrating its quality, manufacturing, clinical, regulatory, and research & development …See details»
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in
Sep 12, 2022 For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our …See details»
Agenus Prioritizes Resources to Accelerate Registration and ...
Aug 23, 2023 The plan will reduce operating expenses across Agenus' global organization by concentrating its quality, manufacturing, clinical, regulatory, and research & development …See details»
Agenus Announces End-of-Phase-2 Meeting Outcomes and …
LEXINGTON, Mass., July 18, 2024--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of …See details»
Clinical - Agenus
Agenus clinical operations infrastructure includes over 200 personnel and spans a full suite of capabilities, ranging from medical writing, data management, safety management, statistics, …See details»
Nature Medicine Reports Agenus’ Novel Immunotherapy …
LEXINGTON, Mass., June 13, 2024--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for …See details»
Agenus Inc. - Agenus Announces End-of-Phase-2 Meeting …
Jul 18, 2024 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced …See details»